EUCTR2021-000904-39-RO进行中（未招募）1 期
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19 - MK-4482 Phase 3 Study for Prevention of COVID-19 in Adults
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,340
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. The participant is a household contact of an index case. The index case is a person with documented COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms case) and must have:
- •a) A first positive SARS-CoV-2 test result from a sample collected within 72 hours prior to randomization of the participant(s), AND
- •b) At least 1 of the following symptoms attributable to COVID-19: fever =38.0ºC, chills, cough, sore throat, shortness of breath or difficulty breathing with exertion, fatigue, nasal congestion, runny nose, headache, muscle or body aches, nausea, vomiting, diarrhea, loss of taste, or loss of smell, with symptom onset no earlier than 5 days prior to randomization of the participant(s).
- •2. The participant does not have confirmed or suspected COVID-19.
- •3. The participant is willing and able to take oral medication.
- •4. The participant is male or female =18 years of age, at the time of providing documented informed consent.
- •5. Male participants are eligible to participate if they agree to the following during the intervention period and for at least 4 days after the last dose of study intervention:
- •Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR
- •Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause) as detailed below:
- •- Agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a WOCBP who is not currently pregnant.
- •- Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- •6. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
- •Is not a WOCBP OR
- •Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), during the intervention period and for at least 4 days after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (ie, noncompliance, recently initiated) in relationship to the first dose of study intervention.
- •- A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention.
- •- The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
- •- Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- •- If contraceptives are interrupted in case of standard of care management of COVID-19 and resumed at a later time point, then abstinence must be practiced for the defined period of back-up contraception per the contraceptive product labeling. After this period, contraceptive use must adhere to protocol.
- •7. The participant’s index case (or legally acceptable representative of the index case) has provided documented informed consent/assent for the collection of COVID-19 documentation requirements.
- •8. The participant
排除标准
- •1. The participant has a prior history of laboratory-confirmed SARS-CoV-2 infection (with or without symptoms).
- •2. The participant is on dialysis or has reduced eGFR <30 mL/min/1.73 m2 (by the MDRD equation).
- •3. The participant has either of the following conditions:
- •HIV with a recent viral load >50 copies/mL (regardless of CD4 count) or an AIDS defining illness in the past 6 months
- •A neutrophilic granulocyte absolute count <500/mm3
- •4. The participant has a history of HBV or HCV infection with any of the following:
- •End-stage liver disease
- •Hepatocellular carcinoma
- •AST and/or ALT >3X upper limit of normal at screening
- •5. The participant has a platelet count <100,000/µL or received a platelet transfusion in the 5 days prior to randomization.
- •6. The participant has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator.
- •7. The participant has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to participants with conditions that could limit gastrointestinal absorption of capsule contents.
- •8. The participant is taking or is anticipated to require any prohibited therapies as outlined in the protocol.
- •9. The participant has received a COVID-19 vaccine with the first dose 7 days or more prior to randomization.
- •10. The participant is unwilling to abstain from participating in another interventional clinical study through Day 29 with an investigational compound or device, including those for COVID-19 therapeutics.
- •11. The participant has more than 1 individual currently (assessed at the time of consent), or within the last month, living in the household with confirmed or suspected COVID-19.
- •12. The participant is living in a household of more than 10 people.
- •13. Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.
研究者
相似试验
进行中（未招募）
1 期
Safety, Tolerability and Immunogenecity of V114 in healthy infants (PNEU-PED-EU-1)Pneumococcal diseaseMedDRA version: 20.0Level: PTClassification code 10061353Term: Pneumococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-003787-31-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,180
进行中（未招募）
3 期
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of SR-0379 in Participants with Skin Ulcerskin ulcerJPRN-jRCT2031210266Ichioka Shigeru120
进行中（未招募）
1 期
A Study on the Effect of E5501 (study drug) in Adults with Chronic Immune ThrombocytopeniaChronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura)MedDRA version: 14.1Level: HLGTClassification code 10035534Term: Platelet disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 14.1Level: PTClassification code 10043554Term: ThrombocytopeniaSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 14.1Level: LLTClassification code 10036735Term: Primary thrombocytopeniaSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 14.1Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2011-000830-12-BEEisai Limited84
已完成
3 期
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitischronic inflammation of the mucous membrane of the large intestineinflammatory bowel disease10017969NL-OMON47446Celgene International II Sarl (CIS II)33
招募中
3 期
Study to Evaluate how effective and safe the investigationall product, Mitapivat, is when administred to Pediatric Subjects With Pyruvate Kinase Deficiency, who are not receiving regular blood transfusions, followed by a 5-Year Open-label Extension Period, where subjects will be given the option to receive mitapivat for an additional 5 years.Pyruvate Kinase Deficiency2024-515025-28-00Agios Pharmaceuticals Inc.14